Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$35.74

0.34 (0.96%)

, MRK

Merck

$58.67

1.07 (1.86%)

11:15
01/12/18
01/12
11:15
01/12/18
11:15

AstraZeneca announces FDA approval of Lynparza for BRCA-mutated breast cancer

AstraZeneca (AZN) and Merck (MRK) announced that the U.S. Food and Drug Administration has approved Lynparza for use in patients with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Patients are selected for therapy based on an FDA-approved companion diagnostic from Myriad Genetics (MYGN), the companies noted. This is the third indication approved for Lynparza in the U.S.

AZN

AstraZeneca

$35.74

0.34 (0.96%)

MRK

Merck

$58.67

1.07 (1.86%)

MYGN

Myriad Genetics

$35.53

0.72 (2.07%)

  • 18

    Jan

  • 25

    Jan

  • 02

    Feb

  • 08

    Feb

  • 16

    Feb

  • 26

    Feb

  • 25

    Mar

  • 03

    Apr

  • 23

    Oct

AZN AstraZeneca
$35.74

0.34 (0.96%)

12/29/17
12/29/17
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. AstraZeneca (AZN) upgraded to Overweight from Neutral at JPMorgan with analyst James Gordon saying the company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium. 2. PriceSmart (PSMT) upgraded to Outperform from Market Perform at IFS Securities. 3. Novo Nordisk (NVO) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he expects "strong" oral semaglutide Phase III newsflow in 2018. 4. Syntel (SYNT) downgraded to Underperform from Market Perform at Wells Fargo with analyst Ed Caso saying he sees the company's "weak" positioning for the ongoing shift in information technology demand from "legacy" low-cost offshore-centric software services to more onshore-necessary "digital" solutions as dragging down its growth and margins. 5. RioCan REIT downgraded to Sector Perform from Outperform at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/29/17
JPMS
12/29/17
UPGRADE
JPMS
Overweight
AstraZeneca upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded AstraZeneca to Overweight and raised his price target for the shares to 55 pounds from 48 pounds. The company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium, Gordon tells investors in a research note. He believes downside risk around the Mystic trial failure and "overly high base business expectations" have now lessened with consensus earnings forecasts declining 15%. The analyst expects AstraZeneca to return to sales growth in 2018, even without further immuno-oncology trial success. Astra has 10 Phase III readouts, with fairly low expectations across the board, Gordon argues.
12/05/17
DBAB
12/05/17
NO CHANGE
DBAB
Buy
AstraZeneca positioned to lead in ovarian cancer, says Deutsche Bank
Deutsche Bank analyst Richard Parkes believes recent "strong data" of Tagrisso/Imfinzi mark a turning point for AstraZeneca and the profitability of its lung cancer franchise. The analyst says his survey of 47 U.S. physicians treating patients with ovarian cancer suggests "strong uptake" of the PARP inhibitors class across multiple lines of therapy. Physicians perceive the various approved drugs as comparable on efficacy but with tolerability favoring AstraZeneca's Lynparza, Parkes tells investors in a research note. He believes AstraZeneca will emerge as market leader in a potential greater than $7B class, with "significant upside potential" to consensus forecasts. The analyst reiterates a Buy rating on the shares.
01/02/18
ADAM
01/02/18
NO CHANGE
Target $77
ADAM
Buy
ANI Pharmaceuticals best positioned in emerging generics space, says Canaccord
Canaccord analyst Dewey Steadman said ANI Pharmaceuticals (ANIP) is one of the best positioned names in the emerging generics space. He noted the company has a basket of additional branded tail assets from its AstraZeneca (AZN) acquisitions, additional cash on hand and credit facilities for future transactions, and a solid core business. Steadman reiterated his Buy rating and raised his price target to $77 from $75 on ANI Pharmaceuticals shares.
MRK Merck
$58.67

1.07 (1.86%)

11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
11/24/17
DBAB
11/24/17
NO CHANGE
Target $59
DBAB
Hold
Deutsche cuts Merck target to $59 on competition from AbbVie, GSK
Deutsche Bank analyst Gregg Gilbert lowered his price target for Merck (MRK) to $59 from $62 citing expectations for more competitive pressure on Zepatier and Zostavax. The stock closed Wednesday up 10c to $54.37. Demand trends for Merck's hepatitis C virus drug Zepatier have continued to decline as AbbVie's (ABBV) Mavyret has gained traction, Gilbert told investors in a research note. The analyst also assumes "significant pressure" on Merck's shingles vaccine Zostavax from the near-term competitive launch of GlaxoSmithKline's (GSK) Shingrix. Gilbert views Merck's risk/reward as fairly balanced and he keeps a Neutral rating on the shares.
11/28/17
BOFA
11/28/17
INITIATION
Target $64
BOFA
Buy
Merck reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Gerberry reinstated coverage on Merck with a Buy and $64 price target citing attractive valuation, diversified revenue streams, pipeline potential, and a history of returning cash.
12/07/17
PIPR
12/07/17
NO CHANGE
PIPR
Roche lung cancer data underwhelming versus Merck's, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss says that while Roche's (RHHBY) IMpower150 data are strong and suggesting a likelihood that the combination of Tecentriq with Avastin and chemo will be approved in non-small cell lung cancer, the data also appear underwhelming compared to Merck's (MRK) KN-21G trial data. The analyst does expect Tecentriq approval in lung cancer next year and reiterates an Overweight rating on Roche. Whether KN-021G represents the "high water mark" for efficacy can only be answered following full presentation of the remaining pivotal Phase 3 trials in this setting, and until then confusion is likely to remain, Purkiss tells investors in a research note. Merck in premarket trading is up 85c to $55.20 while Roche is down 93c to $30.40.
MYGN Myriad Genetics
$35.53

0.72 (2.07%)

09/22/17
SPHN
09/22/17
NO CHANGE
Target $40
SPHN
Overweight
Myriad Genetics price target raised to $40 from $36 at Stephens
Stephens analyst Drew Jones said that after the firm hosted a series of panels with healthcare industry professionals, he believes Myriad Genetics is well positioned to benefit from two key themes that came to the forefront - limiting risk and reducing cost. Jones, who noted that genetic testing was cited repeatedly as a potential lever for cost savings, reiterates his Overweight rating on Myriad and raised his price target on the stock to $40 from $36.
11/02/17
PIPR
11/02/17
NO CHANGE
PIPR
Neutral
Myriad trial hit two important secondary endpoints, says Piper Jaffray
Piper Jaffray analyst William Quirk notes shares of Myriad Genetics are sinking after its key growth asset GeneSight missed the primary endpoint from a large, double blind clinical trial. The study, though, hit two important secondary endpoints that may have a positive impact on longer-term private payer coverage, Quirk tells investors in a research note. The analyst believes the secondary endpoints "may prove to be more important for driving future revenue growth." He keeps a Neutral rating on shares of Myriad Genetics.
11/10/17
JPMS
11/10/17
NO CHANGE
Target $19
JPMS
Underweight
JPMorgan continues to see downside risk in Myriad Genetics
After conducting a survey of high-volume, U.S.-based psychiatrists to get a better sense of the traction GeneSight test is seeing and the longer term market opportunity, JPMorgan analyst Tycho Peterson continues to see risk to the downside in Myriad Genetics shares. Responses overall were mixed, with some indicating GeneSight provides meaningful clinical information while others were cautious on the utility of the test, Peterson tells investors in a research note. The analyst believes the failure of the GeneSight clinical utility study to hit the primary endpoint increases questions on Myriad's ability to gain meaningful incremental reimbursement. He keeps an Underweight rating on the shares with a $19 price target.
12/11/17
PIPR
12/11/17
NO CHANGE
PIPR
Overweight
Piper says CMS coding edits could negatively impact Myriad Genetics
The Centers for Medicare and Medicaid Services made an edit to its procedure guidelines, essentially stating labs should use code 81162, instead of combining 81211 and 81213, Piper Jaffray analyst William Quirk tells investors in a research note. The analyst believes Myriad Genetics bills BRCA tests using the two codes. As such, the edit by CMS could have financial implications for the company as 81162 is paid 21% lower than the combined 81211/81213 rate, Quirk points out. He notes, however, that Myriad management states these coding edits were expected and already factored into guidance. Quirk believes the company's outlook for the second half of 2018 "appears low enough," but he notes that this is the first he's heard about the CMS change. He has a Neutral rating on Myriad with a $29 price target. The stock in morning trading is down 3% to $32.66.

TODAY'S FREE FLY STORIES

SNE

Sony

$51.00

0.2 (0.39%)

, AAPL

Apple

$177.00

-1.46 (-0.82%)

14:25
01/23/18
01/23
14:25
01/23/18
14:25
Downgrade
Sony, Apple rating change  »

Sony downgraded to…

SNE

Sony

$51.00

0.2 (0.39%)

AAPL

Apple

$177.00

-1.46 (-0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

EXAS

Exact Sciences

$48.49

0.67 (1.40%)

14:25
01/23/18
01/23
14:25
01/23/18
14:25
Options
EXACT Sciences call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

MAT

Mattel

$16.09

-0.05 (-0.31%)

, HAS

Hasbro

$90.86

-1.7 (-1.84%)

14:22
01/23/18
01/23
14:22
01/23/18
14:22
Hot Stocks
Breaking Hot Stocks news story on Mattel, Hasbro »

Mattel, Hasbro rally to…

MAT

Mattel

$16.09

-0.05 (-0.31%)

HAS

Hasbro

$90.86

-1.7 (-1.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 20

    Feb

  • 20

    Feb

FB

Facebook

$185.37

4.08 (2.25%)

14:18
01/23/18
01/23
14:18
01/23/18
14:18
Hot Stocks
Facebook CMO leaving to advise other companies, help Democratic Party »

In a status update, Gary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 28

    Feb

$NSD

NASDAQ Market Internals

14:17
01/23/18
01/23
14:17
01/23/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
01/23/18
01/23
14:16
01/23/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$89.35

-1.29 (-1.42%)

14:15
01/23/18
01/23
14:15
01/23/18
14:15
Options
Wayfair put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

TWTR

Twitter

$22.84

-0.5 (-2.14%)

14:13
01/23/18
01/23
14:13
01/23/18
14:13
Recommendations
Twitter analyst commentary  »

Noto departure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

AAPL

Apple

$177.00

-1.46 (-0.82%)

14:10
01/23/18
01/23
14:10
01/23/18
14:10
Periodicals
KGI's Kuo says Apple's next iPhone to have no 3D touch, MacRumors reports »

Apple may launch a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

SNE

Sony

$51.80

0.995 (1.96%)

14:10
01/23/18
01/23
14:10
01/23/18
14:10
Downgrade
Sony rating change  »

Sony downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

14:10
01/23/18
01/23
14:10
01/23/18
14:10
General news
U.S. equities cooled off from record highs »

U.S. equities cooled off…

BTC

Bitcoin

, BITCOIN

Bitcoin

14:09
01/23/18
01/23
14:09
01/23/18
14:09
Hot Stocks
Stripe says ending Bitcoin support »

Tom Karlo, Stripe's…

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REG

Regency Centers

$64.46

0.15 (0.23%)

14:08
01/23/18
01/23
14:08
01/23/18
14:08
Hot Stocks
Regency Centers acquires Whole Foods Market-anchored center in New Jersey »

Regency Centers …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

TEVA

Teva

$20.80

-0.22 (-1.05%)

, JNJ

Johnson & Johnson

$142.63

-5.51 (-3.72%)

14:06
01/23/18
01/23
14:06
01/23/18
14:06
Hot Stocks
NYC sues drug manufacturers, distributors over opioid epidemic »

New York City Mayor Bill…

TEVA

Teva

$20.80

-0.22 (-1.05%)

JNJ

Johnson & Johnson

$142.63

-5.51 (-3.72%)

ENDP

Endo

$7.31

0.2 (2.81%)

MCK

McKesson

$171.56

-1.405 (-0.81%)

CAH

Cardinal Health

$73.46

-0.05 (-0.07%)

ABC

AmerisourceBergen

$102.96

0.3 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 01

    Feb

  • 06

    Feb

  • 08

    Feb

  • 16

    Feb

  • 08

    Mar

SHLD

Sears

$3.45

-0.18 (-4.96%)

14:05
01/23/18
01/23
14:05
01/23/18
14:05
Hot Stocks
Fitch downgrades Sears Holdings to 'C' on distressed debt exchange announcement »

Fitch Ratings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOLD

Amicus

$15.97

0.07 (0.44%)

14:05
01/23/18
01/23
14:05
01/23/18
14:05
Options
Amicus call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSC

Norfolk Southern

$150.81

-0.66 (-0.44%)

14:03
01/23/18
01/23
14:03
01/23/18
14:03
Hot Stocks
Breaking Hot Stocks news story on Norfolk Southern »

Norfolk Southern trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DIS

Disney

$110.10

-1 (-0.90%)

14:01
01/23/18
01/23
14:01
01/23/18
14:01
Hot Stocks
Disney to give over 125,000 employees one-time $1,000 cash bonus »

Disney chairman and CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

JNJ

Johnson & Johnson

$142.74

-5.4 (-3.65%)

14:00
01/23/18
01/23
14:00
01/23/18
14:00
Hot Stocks
Johnson & Johnson Remicade patent loss upheld on appeal »

The United States Court…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

NVS

Novartis

$87.03

0.03 (0.03%)

, CMCSA

Comcast

$42.89

0.39 (0.92%)

13:59
01/23/18
01/23
13:59
01/23/18
13:59
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NVS

Novartis

$87.03

0.03 (0.03%)

CMCSA

Comcast

$42.89

0.39 (0.92%)

GE

General Electric

$16.87

0.7034 (4.35%)

UTX

United Technologies

$135.42

0.2064 (0.15%)

ABT

Abbott

$59.32

-0.2501 (-0.42%)

GD

General Dynamics

$207.58

-0.62 (-0.30%)

ITW

Illinois Tool Works

$172.75

-0.645 (-0.37%)

NSC

Norfolk Southern

$150.90

-0.57 (-0.38%)

BHGE

Baker Hughes

$35.81

0.26 (0.73%)

PGR

Progressive

$57.18

-1.04 (-1.79%)

RCL

Royal Caribbean

$127.33

-1.37 (-1.06%)

SWK

Stanley Black & Decker

$174.31

-0.92 (-0.53%)

ROK

Rockwell Automation

$206.01

2.075 (1.02%)

NTRS

Northern Trust

$107.43

0.94 (0.88%)

GWW

Grainger

$230.43

0.57 (0.25%)

ROL

Rollins

$47.90

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 08

    Feb

  • 16

    Feb

  • 02

    Mar

  • 23

    Apr

  • 17

    May

TXN

Texas Instruments

$119.44

2.61 (2.23%)

, COF

Capital One

$105.09

-0.4 (-0.38%)

13:59
01/23/18
01/23
13:59
01/23/18
13:59
Earnings
Notable companies reporting after market close »

Notable companies…

TXN

Texas Instruments

$119.44

2.61 (2.23%)

COF

Capital One

$105.09

-0.4 (-0.38%)

UAL

United Continental

$77.39

0.52 (0.68%)

TSS

TSYS

$83.64

-0.11 (-0.13%)

NAVI

Navient

$13.52

-0.08 (-0.59%)

CREE

Cree

$36.69

0.4 (1.10%)

FUL

H.B. Fuller

$55.11

0.22 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 21

    Mar

CMCSA

Comcast

$42.89

0.39 (0.92%)

13:57
01/23/18
01/23
13:57
01/23/18
13:57
Technical Analysis
Technical Earnings Preview: Comcast in stable price channel ahead of news »

Shares have been trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

WHR

Whirlpool

$172.58

5.93 (3.56%)

, SSNLF

Samsung

13:50
01/23/18
01/23
13:50
01/23/18
13:50
Hot Stocks
Trump Effect: Whirlpool, solar stocks moving after new import tariffs »

Shares of Whirlpool (WHR)…

WHR

Whirlpool

$172.58

5.93 (3.56%)

SSNLF

Samsung

JKS

JinkoSolar

$21.74

-1.63 (-6.97%)

JASO

JA Solar

$7.46

-0.01 (-0.13%)

FSLR

First Solar

$68.96

-1.07 (-1.53%)

TSLA

Tesla

$351.56

1.54 (0.44%)

RUN

Sunrun

$6.04

0.1 (1.68%)

VSLR

Vivint Solar

$3.78

0.225 (6.34%)

SPWR

SunPower

$8.72

0.07 (0.81%)

CSIQ

Canadian Solar

$15.77

-0.03 (-0.19%)

YGE

Yingli Green Energy

$1.82

-0.0699 (-3.70%)

SEDG

SolarEdge

$34.75

-0.45 (-1.28%)

ENPH

Enphase Energy

$1.97

0.02 (1.03%)

SKYS

Sky Solar

$1.21

-0.12 (-9.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 30

    Jan

  • 14

    Feb

  • 26

    Feb

CCL

Carnival

$69.03

0.17 (0.25%)

13:50
01/23/18
01/23
13:50
01/23/18
13:50
Options
Carnival Cruise weekly call buyer as shares tick higher »

Carnival Cruise weekly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAYX

Paychex

$69.70

0.21 (0.30%)

, MTB

M&T Bank

$189.46

0.7 (0.37%)

13:47
01/23/18
01/23
13:47
01/23/18
13:47
Periodicals
Paychex founder open to merger talks with M&T Bank, Buffalo Chronicle says »

In a report published…

PAYX

Paychex

$69.70

0.21 (0.30%)

MTB

M&T Bank

$189.46

0.7 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.